Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with no cure and limited treatment options. There is therefore an urgent need for effective therapeutic interventions in this disease. This protocol outlines the strategy for a systematic review and meta-analysis to identify, from in vivo animal and human induced pluripotent stem cell (hiPSC) studies, potential therapeutic interventions for ALS. Our aim is to perform a comprehensive review of the ALS literature to compile a list of (1) candidate interventions and (2) target pathways that may be of therapeutic benefit in patients with ALS. 
K E Y W O R D S
ALS
| APPROACH
A systematic review will be performed assessing interventions implemented in preclinical data from all in vivo models of ALS and frontotemporal dementia (FTD) (given the clinical and genetic overlap between the diseases) including (1) mammalian models (mouse and rat), (2) Intervention: all therapeutic interventions.
Comparison: control or vehicle treatment group.
| Outcome measure
Primary outcome: mortality (spontaneous or euthanased); for hiPSCs, cell death.
Secondary outcomes: (1) Study design: all study types where outcome in animals or cells exposed to the intervention is compared with that in animals or cells not exposed to the intervention. 
| METHODS

| Search (2) iPSC data
| Screening
We will use the Systematic Review Facility online screening tool (app.syrf.org.uk). We will screen the title and abstract of each paper identified and for potentially relevant papers the full text will be retrieved, imported to EndNote and duplicate records will be discarded. Two independent reviewers will assess each paper (for screening and data extraction) with regards to the inclusion and exclusion criteria and a quality score and will extract data as described below. If reviewer concordance is <0.66 a third reviewer will assess the paper.
| Eligibility
| Inclusion criteria
• All therapeutic interventions where outcome is compared with that in a control or placebo group in ALS or FTD disease models.
• Types of model.
• Genetic (knock out/in) OR drug induced (not combinations).
• Yeast, Drosophila, Zebrafish, C. elegans, Mouse, Rat, human induced pluripotent stem cells (hiPSCs).
| Exclusion criteria
• No control group.
• Clinical studies.
• Reviews.
• Letters and comments.
• Co-treatments.
• Combinations of genetic and pharmacological induction of phenotype.
• Cancer cell lines and all non-human iPSC lines.
| Quality checklist
CAMARADES' study quality checklist, adapted as follows:
Nine items will be considered, and the median number of checklist items scored, and the interquartile range, will be calculated.
• Peer review publication.
• Statement of potential conflict of interests.
• Sample size calculation.
• Random allocation to group.
• Allocation concealment.
• Blinded assessment of outcome.
• Appropriate control group identified.
• Compliance with animal welfare regulations.
• Statement of temperature control.
Study characteristics to be extracted:
• Study ID: (1) author and (2) • Type of therapy: (1) immune, (2) genetic, (3) pharmacological, (4) environmental (e.g. diet/temperature), (5) cell.
• Target pathway: (1) Calcium homeostasis, (2) excitotoxicity, (3) protein turnover, (4) apoptosis, (5) regeneration (6) trophic factor signalling, (7) immunomodulation, (8) inflammation, (9) oxidative stress, (10) anion channel abnormalities, (11) lipid metabolism, (12) energy balance (including mitochondrial disruption and (13) axon transport.
• Mode of intervention delivery: (oral, intrathecal, intracerebroventricular, intraventricular, intraspinal, intraparenchymal dialysis catheter, intracranial cell transplantation/injection, subcutaneous, intravenous, intramuscular, intraperitoneal).
• Sample size.
• Duration of intervention (1) single or (2) multiple or (3) continuous.
• Natural death or euthanased or N/A.
• Outcome: (1) outcome measure (2) primary or secondary (3) value.
| Statistical analysis
An individual meta-analysis will be carried out for each intervention identified and a subgroup analysis of interventions grouped by putative biological target will also be performed. Additional subgroup analyses will include (1) assessment of SOD1 G93A mouse model control-group survival data for evidence of genetic drift with time and (2) comparison of efficacy of treatments and targets separately in sporadic and familial models of disease.
The outcome measures will be plotted for each of the studies identified and included on a forest plot. Given the variability of model organisms included in the analysis, primary outcome data (survival summary data) will be calculated as described previously 4 and secondary outcome measures will be recorded in standardised mean differences (SMD), to allow meaningful comparisons between studies. SMD will be compared using Hedges g statistic, to account for bias from small sample sizes, using a random effects model. Survival summary measures and SMDs will be reported as odds ratios with 95% confidence intervals. Heterogeneity will be assessed for all outcome measures using I 2 values, and a funnel plot and Egger's regression test will be used to assess publication bias. The summary data from each analysis will then be compared to the other meta-analyses on a separate forest plot and a hierarchy of candidate interventions will be identified.
